Flavio Mantelli & OKYO Pharma
4 shared events · Importance 3 · Last updated Jul 23, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Flavio Mantelli is the Chief Medical Officer of OKYO Pharma, overseeing the company's clinical development strategy. He also holds a minor equity stake in the company, including recently purchased shares and options.
Regulatory
Flavio Mantelli: Flavio Mantelli, Chief Medical Officer, highlighted the FDA feedback as an important milestone and de-risking of the development program.
OKYO Pharma: OKYO Pharma received positive FDA feedback validating its clinical path for urcosimod, de-risking the program and supporting advancement into a global Phase 3 trial. This milestone could enhance the company's valuation and prospects.
Jul 08, 2026 · 9 articles
Business
Flavio Mantelli: Chief Medical Officer purchased 20,000 shares at $1.40.
OKYO Pharma: OKYO Pharma is the subject of insider buying, indicating management confidence. The company is preparing for a Phase 3 trial of urcosimod for NCP.
Jul 21, 2026 · 22 articles
Business
Flavio Mantelli: Flavio Mantelli>>>, Chief Medical Officer of OKYO Pharma>>>, commented on the strengthening of the Scientific Advisory Board with Marta Sacchetti>>>'s appointment.
OKYO Pharma: OKYO Pharma>>> expanded its Scientific Advisory Board with the appointment of Marta Sacchetti>>> to strengthen its expertise in neuro-inflammatory corneal diseases and advance its clinical programs for Urgoskin.
May 19, 2026 · 7 articles
Business
Flavio Mantelli: Chief Medical Officer of OKYO Pharma, presenting at the symposium.
OKYO Pharma: OKYO Pharma is the subject of the announcement, participating in the symposium to present its clinical developments.
Jul 07, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Flavio Mantelli and OKYO Pharma interact across events, view sentiment trends, and discover connected entities.
Open Dashboard